181 related articles for article (PubMed ID: 22498110)
1. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
Donohue JF; Anzueto A; Brooks J; Mehta R; Kalberg C; Crater G
Respir Med; 2012 Jul; 106(7):970-9. PubMed ID: 22498110
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
3. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients.
Decramer M; Maltais F; Feldman G; Brooks J; Harris S; Mehta R; Crater G
Respir Physiol Neurobiol; 2013 Jan; 185(2):393-9. PubMed ID: 23026438
[TBL] [Abstract][Full Text] [Related]
4. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Feldman G; Walker RR; Brooks J; Mehta R; Crater G
Pulm Pharmacol Ther; 2012 Dec; 25(6):465-71. PubMed ID: 22955035
[TBL] [Abstract][Full Text] [Related]
5. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Verkindre C; Fukuchi Y; Flémale A; Takeda A; Overend T; Prasad N; Dolker M
Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
Bateman E; Feldman G; Kilbride S; Brooks J; Mehta R; Harris S; Maden C; Crater G
Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
[TBL] [Abstract][Full Text] [Related]
7. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
Fogarty C; Hattersley H; Di Scala L; Drollmann A
Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
Sterling R; Lim J; Frith L; Snowise NG; Jacques L; Haumann B
Respir Med; 2012 Aug; 106(8):1110-5. PubMed ID: 22520084
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
11. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
12. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
Church A; Beerahee M; Brooks J; Mehta R; Shah P
BMC Pulm Med; 2014 Jan; 14():2. PubMed ID: 24393134
[TBL] [Abstract][Full Text] [Related]
13. Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
Donohue JF; Kalberg C; Shah P; Beerahee M; Mehta R; Gunawan R; Church A
J Clin Pharmacol; 2014 Nov; 54(11):1214-20. PubMed ID: 24895108
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
[TBL] [Abstract][Full Text] [Related]
15. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
17. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
van Noord JA; Smeets JJ; Drenth BM; Rascher J; Pivovarova A; Hamilton AL; Cornelissen PJ
Pulm Pharmacol Ther; 2011 Dec; 24(6):666-72. PubMed ID: 21839850
[TBL] [Abstract][Full Text] [Related]
18. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
[TBL] [Abstract][Full Text] [Related]
19. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE
Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
